BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 11891608)

  • 1. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
    Hansen G; Hoffjan S; Mosler K; Schuster A
    Lung; 2001; 179(3):185-94. PubMed ID: 11891608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha 1-proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum.
    Hansen G; Schuster A; Zubrod C; Wahn V
    Respiration; 1995; 62(3):117-24. PubMed ID: 7569330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolastin aerosol therapy and sputum taurine in cystic fibrosis.
    Cantin AM; Berthiaume Y; Cloutier D; Martel M
    Clin Invest Med; 2006 Aug; 29(4):201-7. PubMed ID: 16986483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
    Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
    Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
    Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
    Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis.
    Shah PL; Scott SF; Knight RA; Hodson ME
    Eur Respir J; 1996 Mar; 9(3):531-4. PubMed ID: 8730015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M; Dasgupta B; Tomkiewicz RP; Brown NE
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of native and oxidation-resistant secretory leukoprotease inhibitor on cystic fibrosis sputum: inhibition of neutrophil elastase activity and of sputum-induced secretion from porcine tracheal submucosal glands.
    Schuster A; Hansen G; Zubrod-Eichert C; Wahn V
    Pediatr Res; 1996 Nov; 40(5):732-7. PubMed ID: 8910939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis.
    Sanders NN; Franckx H; De Boeck K; Haustraete J; De Smedt SC; Demeester J
    Thorax; 2006 Nov; 61(11):962-8. PubMed ID: 17071834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
    Dasgupta B; King M
    Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice.
    Cantin AM
    Am J Respir Crit Care Med; 1998 Feb; 157(2):464-9. PubMed ID: 9476859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
    Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
    Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
    Suri R; Metcalfe C; Wallis C; Bush A
    Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of neutrophil elastase in CF sputum by L-658,758.
    Rees DD; Brain JD; Wohl ME; Humes JL; Mumford RA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1201-6. PubMed ID: 9399994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
    Zahm JM; Debordeaux C; Maurer C; Hubert D; Dusser D; Bonnet N; Lazarus RA; Puchelle E
    Am J Respir Crit Care Med; 2001 Apr; 163(5):1153-7. PubMed ID: 11316652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.
    Costello CM; O'Connor CM; Finlay GA; Shiels P; FitzGerald MX; Hayes JP
    Thorax; 1996 Jun; 51(6):619-23. PubMed ID: 8693445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha.
    Ratjen F; Paul K; van Koningsbruggen S; Breitenstein S; Rietschel E; Nikolaizik W
    Pediatr Pulmonol; 2005 Jan; 39(1):1-4. PubMed ID: 15532079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.
    Griese M; Latzin P; Kappler M; Weckerle K; Heinzlmaier T; Bernhardt T; Hartl D
    Eur Respir J; 2007 Feb; 29(2):240-50. PubMed ID: 17050563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase.
    Brandt T; Breitenstein S; von der Hardt H; Tümmler B
    Thorax; 1995 Aug; 50(8):880-2. PubMed ID: 7570441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum.
    Dubois AV; Midoux P; Gras D; Si-Tahar M; Bréa D; Attucci S; Khelloufi MK; Ramphal R; Diot P; Gauthier F; Hervé V
    Am J Respir Crit Care Med; 2013 Sep; 188(6):703-9. PubMed ID: 23947381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.